Literature DB >> 31830820

Jairo Vinícius Pinto1,2, Gayatri Saraf1, Christian Frysch1, Daniel Vigo1, Kamyar Keramatian1, Trisha Chakrabarty1, Raymond W Lam1, Márcia Kauer-Sant'Anna2, Lakshmi N Yatham1.   

Abstract

Entities:  

Keywords:  affective disorders; bipolar disorder; cannabidiol; cannabinoids; depressive disorders; major depressive disorder; mania; mood disorders

Mesh：

Substances：

Year:  2019        PMID： 31830820      PMCID： PMC7385425          DOI： 10.1177/0706743719895195

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


× No keyword cloud information.
  132 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study.

Authors:  Laura Kranaster; Carolin Hoyer; Suna Su Aksay; Jan Malte Bumb; F Markus Leweke; Christoph Janke; Manfred Thiel; Beat Lutz; Laura Bindila; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-24       Impact factor: 5.270

3.  Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia.

Authors:  Marco Aurélio Mori; Erika Meyer; Ligia Mendes Soares; Humberto Milani; Francisco Silveira Guimarães; Rúbia Maria Weffort de Oliveira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-11-23       Impact factor: 5.067

4.  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors:  Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

5.  Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.

Authors:  Massimiliano Aragona; Emanuela Onesti; Valentina Tomassini; Antonella Conte; Shiva Gupta; Francesca Gilio; Patrizia Pantano; Carlo Pozzilli; Maurizio Inghilleri
Journal:  Clin Neuropharmacol       Date:  2009 Jan-Feb       Impact factor: 1.592

6.  Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.

Authors:  Davy Vancampfort; Kristof Vansteelandt; Christoph U Correll; Alex J Mitchell; Amber De Herdt; Pascal Sienaert; Michel Probst; Marc De Hert
Journal:  Am J Psychiatry       Date:  2013-03       Impact factor: 18.112

7.  Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study.

Authors:  Bartholomeus C M Benno Haarman; Rixt F Riemersma-Van der Lek; Jan Cees de Groot; Henricus G Eric Ruhé; Hans C Klein; Tjitske E Zandstra; Huibert Burger; Robert A Schoevers; Erik F J de Vries; Hemmo A Drexhage; Willem A Nolen; Janine Doorduin
Journal:  Brain Behav Immun       Date:  2014-04-03       Impact factor: 7.217

8.  Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study.

Authors:  Arpana Agrawal; Elliot C Nelson; Kathleen K Bucholz; Rebecca Tillman; Richard A Grucza; Dixie J Statham; Pamela Af Madden; Nicholas G Martin; Andrew C Heath; Michael T Lynskey
Journal:  Lancet Psychiatry       Date:  2017-07-24       Impact factor: 27.083

9.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

10.  Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies.

Authors:  Qian He; Xiaohua Chen; Tang Wu; Liyuan Li; Xiaofan Fei
Journal:  J Clin Neurol       Date:  2018-10-26       Impact factor: 3.077
View more
  5 in total

1.  Cannabidiol for Mood Disorders: A Call for More Research.

Authors:  Francesco Bartoli; Bianca Bachi; Angela Calabrese; Federico Moretti; Cristina Crocamo; Giuseppe Carrà
Journal:  Can J Psychiatry       Date:  2020-05-14       Impact factor: 4.356

Review 2.  A scoping review of the use of cannabidiol in psychiatric disorders.

Authors:  Anna E Kirkland; Matthew C Fadus; Staci A Gruber; Kevin M Gray; Timothy E Wilens; Lindsay M Squeglia
Journal:  Psychiatry Res       Date:  2021-12-20       Impact factor: 3.222

Review 3.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Authors:  Vicente Martínez; Amaia Iriondo De-Hond; Francesca Borrelli; Raffaele Capasso; María Dolores Del Castillo; Raquel Abalo
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 4.  Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression.

Authors:  Ines Gallego-Landin; Alba García-Baos; Adriana Castro-Zavala; Olga Valverde
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

Review 5.  Existing and emerging pharmacological approaches to the treatment of mania: A critical overview.

Authors:  Giulio Sparacino; Norma Verdolini; Eduard Vieta; Isabella Pacchiarotti
Journal:  Transl Psychiatry       Date:  2022-04-23       Impact factor: 7.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.